Warsaw Orthopedic, Inc.

Medtronic, Inc.

John Myers Zanella

William F McKay

Vanja Margareta King

Christopher M Hobot

Kathy L Remsen

Danielle L Biggs

Katara Shaw

Stephen Mark Cox

Jared T Wilsey

Josee Roy

Jeffrey C Marx

Phillip Edward McDonald

Sean M Haddock

Danielle L Clay

Thomas Andrew Simonton

Sara D Waynick

Susan J Drapeau

Jeffrey Mendel Gross

Keith Robert Hildebrand

Lisa Lynn Shafer

Catherine E Taylor

Steven Marquis Peckham

Eric Burright

Toya Kimble

Kathryn J Kitching

S Mark Cox

Bill McKay

Jonathan K Gray

Erica Tenbroek

Eric N Burright

William F Mckay

Phillip Edward Mcdonald

Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine and a gamma-aminobutyric acid compound at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Clonidine and GABA compounds in a biodegradable polymer carrier

Pharmaceutical gels and methods for delivering a therapeutic agent to a target tissue site beneath the skin of a patient are provided, the gel being capable of adhering to the target tissue site and comprising one or more biodegradable depots containing an effective amount of the therapeutic agent. In various embodiments, the gel is sprayable and hardens after contacting the target tissue site.

Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin

Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Clonidine formulations in a biodegradable polymer carrier

Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to reduce, prevent or treat sciatic pain and/or inflammation. In various embodiments, prevent transplant rejection for at least twenty-five days. In some embodiments, the pain relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Fluocinolone formulations in a biodegradable polymer carrier

Effective treatments of acute pain for extended periods of time are provided. Through the administration of an effective amount of dexamethasone at or near a target site, one can relieve pain cause by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Dexamethasone formulations in a biodegradable material

Methods and compositions are provided for treating an intervertebral disc herniation by local administration of one or more biodegradable drug depots comprising a therapeutically effective amount of a glucocorticoid at or near the intervertebral disc herniation to reduce the size of the intervertebral disc herniation.

Methods and compositions for treating intervertebral disc herniations

A drug cartridge is provided for delivering a drug pellet to a site beneath the skin of a patient, the drug cartridge comprising: two or more chambers, each chamber holding a drug pellet and having a proximal end and a distal end, the proximal end of the chamber having an opening to receive the drug pellet and a plunger, the distal end of the chamber having an opening for receiving the plunger and passage of the drug pellet, a bulking agent disposed within at least a portion of each chamber, wherein movement of the plunger to an extended position moves the drug pellet within the chamber of the cartridge out the distal end of the chamber and out of the drug cartridge. In some embodiments, instead or with the bulking agent pierceable superior and inferior covers are used to contain the drug pellets.

Drug cartridge for delivering a drug depot comprising a bulking agent and/or cover

Effective treatments of pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulindac or a pharmaceutically acceptable salt thereof at or near a target site, one can relieve pain and/or inflammation caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days, at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

Sulindac formulations in a biodegradable material

Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment pain by inhibiting the NF&#x3ba;B family of transcription factors.

Systems and methods to treat pain locally

Effective treatments of pain and/or inflammation from tendonitis, carpal tunnel syndrome, tarsal tunnel syndrome, osteoarthritis, bursitis and/or an oral-facial disease are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation from tendonitis, carpal tunnel syndrome, tarsal tunnel syndrome, osteoarthritis, bursitis and/or an oral-facial disease.

Alpha adrenergic receptor agonists for treatment of inflammatory diseases

Growing community of inventors

Cordova, TN, United States of America

John Myers Zanella